Nanoparticle Formulation Market by Type of Nanoparticle (Organic, Inorganic Nanoparticles and Carbon-based Nanoparticles), Scale of Operation and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

As per Roots Analysis, the global nanoparticle formulation market is estimated to grow from USD 5.1 billion in the current year to USD 15.1 billion by 2035, at a CAGR of 9.4% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Nanoparticle Formulated

Organic Nanoparticles
Inorganic Nanoparticles
Carbon-based Nanoparticles

Type of Organic Nanoparticle Formulated

Polymeric Nanoparticles
Lipid Nanoparticles
Viral Nanoparticles
Protein-based Nanoparticles
Other Organic Nanoparticles

Scale of Operation

Preclinical
Clinical
Commercial

Key Geographical Regions

North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America

NANOPARTICLE FORMULATION MARKET: GROWTH AND TRENDS

Having demonstrated a strong therapeutic potential across a myriad of diseases, nanoparticle-based drugs have emerged as a promising treatment alternative within a short span. In fact, given the current ongoing pace of research, experts believe that remarkable innovations in the field of nanoparticles (in terms of improvement in disease diagnosis and treatment specificity) are likely to revolutionize the pharma industry in the coming years. Furthermore, the recent initiatives focused on nanotechnology for the detection and control of vector-borne diseases, dialysis, and molecular imaging, have further fueled the demand for these nanoparticles. In addition, the nanoparticles can be engineered to achieve optimal delivery and overcome the limitations of biological barriers (systemic, microenvironmental and cellular) in the patient's body owing to their modifiable properties (such as size, shape, surface properties and charge). However, the complex interplay between nanoparticle properties and biological systems requires careful consideration to ensure the safety and efficacy of these nanoscale materials. Various stakeholders, such as contract research organizations, (CROs), and contract development and manufacturing organizations (CDOs / CDMOs) are likely to play a pivotal role in supporting researchers and drug developers to navigate the complexities associated with its design, development and manufacturing. By leveraging the multifaceted expertise in the field, contract service providers can help streamline the nanoparticle development process, reduce costs, and accelerate the translation of promising nanoparticles from lab scale to clinical scale. Driven by technological advancements and the rising demand for nanoparticle-based drugs, the nanoparticle formulation services market is anticipated to witness notable growth in the foreseen future.

NANOPARTICLE FORMULATION MARKET: KEY INSIGHTS

The report delves into the current state of the nanoparticle formulation market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Presently, more than 100 nanoparticle formulation technologies are being offered by companies across the globe in order to augment the development and manufacturing of nanoparticle-based drugs.
Close to 80% of technologies are designed for the formulation of organic nanoparticles; of these, nearly 50% are intended for drug delivery via injectable route, primarily targeting oncological disorders.
The current service providers landscape has over 80 companies offering a wide range of nanoparticle formulation services at various scales of operation.

The market landscape features the presence of both well-established players and new entrants with the requisite expertise to develop / manufacture nanoparticle-based drugs for an extensive range of application areas.
Owing to the rise in demand for nanoparticle-based formulations, service providers are continuously expanding their existing capabilities to enhance their respective service portfolios.
A steady growth in the partnership activity has been observed in recent years; R&D agreements have been the most prominent type of partnership model adopted by players based in the US.
More than 1,700 patents related to nanoparticle formulation and development have been filed by / granted to various organizations in order to protect intellectual property.
The nanoparticle formulation services market is likely to grow at a CAGR of ~9% over the next decade, driven by revenues generated from commercial scale operation.

NANOPARTICLE FORMULATION MARKET: KEY SEGMENTS

Organic Nanoparticles are Likely to Dominate the Nanoparticle Formulation Market During the Forecast Period

Based on the type of nanoparticle, the market is segmented into organic nanoparticles, inorganic nanoparticles and carbon-based nanoparticles. At present, organic nanoparticles hold the maximum share of the nanoparticle formulation market. This trend is unlikely to change in the near future.

Protein-based Nanoparticles Segment is the Fastest Growing Segment of the Nanoparticle Formulation Market During the Forecast Period

Based on the type of organic nanoparticle, the market is segmented into polymeric nanoparticles, lipid nanoparticles, viral nanoparticles, protein-based nanoparticles, and other organic nanoparticles. It is worth highlighting that, currently, lipid nanoparticles hold a larger share of the nanoparticle formulation market. However, the nanoparticle formulation market for protein-based nanoparticles is likely to grow at a higher CAGR in the coming decade.

Commercial Operations Occupy the Largest Share of the Nanoparticle Formulation Market

Based on scales of operation, the market is segmented into preclinical, clinical and commercial scales. At present, commercial operations capture the maximum share of the nanoparticle formulation market. It is worth highlighting that the nanoparticle formulation market at the clinical scale is likely to grow at a higher CAGR in the near future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. The majority share is expected to be captured by service providers based in North America and Europe. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Nanoparticle Formulation Market

Ascension Sciences
DIANT Pharma
ExonanoRNA
Nanoform
NanoVation Therapeutics
NanoVelos
NTT Biopharma
Organoid-X BioTech
Vaxinano

NANOPARTICLE FORMULATION MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the nanoparticle formulation market, focusing on key market segments, including [A] type of nanoparticle formulated, [B] type of organic nanoparticle formulated, [C] scale of operation and [D] key geographical regions.
Market Landscape 1: A comprehensive evaluation of nanoparticle formulation technologies, considering various parameters, such as [A] type of nanoparticle(s) formulated, [B] type of molecule(s) delivered, [C] therapeutic area(s), [D] compatible dosage form(s) and [E] route(s) of administration. Further, the chapter provides information on various technology developers, along with analysis based on multiple parameters, such as [F] year of establishment, [G] company size, [H] location of headquarters and [I] most active players (in terms of number of technologies developed).
Market Landscape 2: A comprehensive evaluation of nanoparticle formulation service providers, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] location of facilities, [E] type of service provider(s), [F] type of nanoparticle(s) formulated, [G] type of service(s) offered, [H] scale of operation and [I] application area(s).
Technology Competitiveness: A comprehensive competitive analysis of nanoparticle formulation technologies, examining factors, such as [A] developer power, [B] technology strength and [C] technology applicability.
Company Competitiveness: A comprehensive competitive analysis of nanoparticle formulation service providers, examining factors, such as [A] company strength and [B] service strength.
Company Profiles: In-depth profiles of key industry players offering technologies and services for nanoparticle formulation across North America, Europe and Asia-Pacific, focusing on [A] company overviews, [B] technology portfolio, [C] service portfolio, [D] recent developments and [E] an informed future outlook.
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering technology licensing agreements, research and development agreements, product development agreements, manufacturing agreements, mergers and acquisitions, technology integration agreements and other relevant agreements.
Patent Analysis: Detailed analysis of various patents filed / granted related to nanoparticle formulation based on [A] publication year, [B] geographical region, [C] CPC symbols, [D] leading players (in terms of number of patents filled / granted) and [E] type of organization. It also includes a patent benchmarking analysis and a detailed valuation analysis.
Nanoparticle Evaluation Framework: An insightful framework evaluating types of nanoparticles based on various parameters, such as [A] number of technologies, [B] nanoparticle efficacy, [C] number of clinical trials evaluating nanoparticle-based drugs, [D] extent of innovation, [E] trends in research activity and [F] current global competition. It also provides a value addition matrix for respective types of nanoparticles currently adopted by stakeholders.
Case Study: A case study of the recent technology licensing agreements, along with information on deal amounts.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100437

1. PREFACE

1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Introduction to Nanoparticles
3.3. Classification of Nanoparticles
- 3.3.1. Organic Nanoparticles
- 3.3.2. Inorganic Nanoparticles
- 3.3.3. Carbon-based Nanoparticles
3.4. Methods of Nanoparticle Formulation
3.5. Applications of Nanoparticle-based Systems
3.6. Challenges associated with Nanoparticle Formulation
3.7. Need for Outsourcing Nanoparticle Formulation
3.8 Concluding Remarks

4. TECHNOLOGY LANDSCAPE

4.1. Chapter Overview
4.2. Nanoparticle Formulation: Technology Landscape
- 4.2.1. Analysis by Type of Nanoparticle(s) Formulated
- 4.2.2. Analysis by Type of Organic Nanoparticle(s) Formulated
- 4.2.3. Analysis by Type of Inorganic Nanoparticle(s) Formulated
- 4.2.4. Analysis by Type of Molecule(s) Delivered
- 4.2.5. Analysis by Therapeutic Area(s)
- 4.2.6. Analysis by Compatible Dosage Form(s)
- 4.2.7. Analysis by Route(s) of Administration
4.3. Nanoparticle Formulation: Technology Developer Landscape
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters
- 4.3.4. Analysis by Company Size and Location of Headquarters
- 4.3.5. Most Active Players: Analysis by Number of Technologies

5. SERVICE PROVIDERS LANDSCAPE

5.1. Chapter Overview
5.2. Nanoparticle Formulation: Service Providers Landscape
- 5.2.1. Analysis by Year of Establishment
- 5.2.2. Analysis by Company Size
- 5.2.3. Analysis by Location of Headquarters
- 5.2.4. Analysis by Company Size and Location of Headquarters
- 5.2.5. Analysis by Location of Facilities
- 5.2.6. Analysis by Type of Service Provider(s)
- 5.2.7. Analysis by Type of Nanoparticle(s) Formulated
  - 5.2.7.1. Analysis by Type of Organic Nanoparticle(s) Formulated
  - 5.2.7.2. Analysis by Type of Inorganic Nanoparticle(s) Formulated
- 5.2.8. Analysis by Type of Service Provider(s) and Type of Nanoparticle(s) Formulated
- 5.2.9. Analysis by Service(s) Offered
- 5.2.10. Analysis by Company Size and Service(s) Offered
- 5.2.11. Analysis by Scale of Operation
- 5.2.12. Analysis by Application Area(s)

6. TECHNOLOGY COMPETITIVENESS ANALYSIS

6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
- 6.4.1. Nanoparticle Formulation Technologies Offered by Players based in North America
  - 6.4.1.1. Nanoparticle Formulation Technologies Offered by Small Players based in North America
  - 6.4.1.2. Nanoparticle Formulation Technologies Offered by Mid-sized and Large Players based in North America
- 6.4.2. Nanoparticle Formulation Technologies Offered by Players based in Europe
- 6.4.3. Nanoparticle Formulation Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Rest of the World

7. COMPANY COMPETITIVENESS ANALYSIS

7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
- 7.4.1. Nanoparticle Formulation Service Providers based in North America
- 7.4.2. Nanoparticle Formulation Service Providers based in Europe
- 7.4.3. Nanoparticle Formulation Service Providers based in Asia-Pacific, Middle East and North Africa

8. COMPANY PROFILES

8.1. Chapter Overview
8.2. Ascension Sciences
- 8.2.1. Company Overview
- 8.2.2. Technology Portfolio
- 8.2.3. Service Portfolio
- 8.2.4. Recent Developments and Future Outlook
8.3. DIANT Pharma
- 8.3.1. Company Overview
- 8.3.2. Technology Portfolio
- 8.3.3. Service Portfolio
- 8.3.4. Recent Developments and Future Outlook
8.4. ExonanoRNA
- 8.4.1. Company Overview
- 8.4.2. Technology Portfolio
- 8.4.3. Service Portfolio
- 8.4.4. Recent Developments and Future Outlook
8.5. Nanoform
- 8.5.1. Company Overview
- 8.5.2. Technology Portfolio
- 8.5.3. Service Portfolio
- 8.5.4. Recent Developments and Future Outlook
8.6. NanoVation Therapeutics
- 8.6.1. Company Overview
- 8.6.2. Technology Portfolio
- 8.6.3. Service Portfolio
- 8.6.4. Recent Developments and Future Outlook
8.7. NanoVelos
- 8.7.1. Company Overview
- 8.7.2. Technology Portfolio
- 8.7.3. Service Portfolio
- 8.7.4. Recent Developments and Future Outlook
8.8. NTT Biopharma
- 8.8.1. Company Overview
- 8.8.2. Technology Portfolio
- 8.8.3. Service Portfolio
- 8.8.4. Recent Developments and Future Outlook
8.9. Organoid-X BioTech
- 8.9.1. Company Overview
- 8.9.2. Technology Portfolio
- 8.9.3. Service Portfolio
- 8.9.4. Recent Developments and Future Outlook
8.10. Vaxinano
- 8.10.1. Company Overview
- 8.10.2. Technology Portfolio
- 8.10.3. Service Portfolio
- 8.10.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Nanoparticle Formulation Technologies and Services: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Year and Type of Partnership
- 9.3.4. Analysis by Type of Partner
- 9.3.5. Analysis by Location of Headquarters of Partner
- 9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
- 9.3.7. Most Active Players: Analysis by Number of Partnerships
- 9.3.8. Analysis by Geography
  - 9.3.8.1. Intercontinental and Intracontinental Deals
  - 9.3.8.2. Local and International Deals

10. PATENT ANALYSIS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Nanoparticle Formulation Domain: Patent Analysis
- 10.3.1. Analysis by Publication Year
- 10.3.2. Analysis by Type of Patent and Publication Year
- 10.3.3. Analysis by Geography
- 10.3.4. Analysis by CPC Symbols
- 10.3.5. Analysis by Type of Organization
- 10.3.6. Leading Industry Players: Analysis by Number of Patents
10.4. Patent Benchmarking Analysis
- 10.4.1. Analysis by Patent Characteristics
10.5. Patent Valuation Analysis

11. NANOPARTCLE EVALUATION FRAMEWORK

11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Organic Nanoparticles
- 11.3.1. Number of Clinical Trials
- 11.3.2 Extent of Innovation
- 11.3.3. Trends in Research Activity
- 11.3.4. Current Global Competition
- 11.3.5. Nanoparticle Evaluation Framework: Organic Nanoparticles
11.4. Inorganic Nanoparticles
- 11.4.1. Number of Clinical Trials
- 11.4.2 Extent of Innovation
- 11.4.3. Trends in Research Activity
- 11.4.4. Current Global Competition
- 11.4.5. Nanoparticle Evaluation Framework: Inorganic Nanoparticles
11.5. Carbon-based Nanoparticles
- 11.5.1. Number of Clinical Trials
- 11.5.2 Extent of Innovation
- 11.5.3. Trends in Research Activity
- 11.5.4. Current Global Competition
- 11.5.5. Nanoparticle Evaluation Framework: Carbon-based Nanoparticles
- 11.5.6. Nanoparticle Evaluation Framework: Concluding Remarks

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Nanoparticle Formulation Services Market, till 2035
12.4. Nanoparticle Formulation Services Market: Analysis by Type of Nanoparticle Formulated
- 12.4.1. Nanoparticle Formulation Services Market: Analysis by Type of Organic Nanoparticle Formulated
  - 12.4.1.1. Nanoparticle Formulation Services Market for Polymeric Nanoparticles, till 2035
  - 12.4.1.2. Nanoparticle Formulation Services Market for Lipid Nanoparticles, till 2035
  - 12.4.1.3. Nanoparticle Formulation Services Market for Viral Nanoparticles, till 2035
  - 12.4.1.4. Nanoparticle Formulation Services Market for Protein-based Nanoparticles, till 2035
  - 12.4.1.5. Nanoparticle Formulation Services Market for Other Organic Nanoparticles, till 2035
- 12.4.2. Nanoparticle Formulation Services Market: Analysis by Inorganic Nanoparticle Formulated
- 12.4.3. Nanoparticle Formulation Services Market: Analysis by Carbon-based Nanoparticle Formulated
12.5. Nanoparticle Formulation Services Market: Analysis by Scale of Operation
- 12.5.1. Nanoparticle Formulation Services Market for Preclinical Operations, till 2035
- 12.5.2. Nanoparticle Formulation Services Market for Clinical Operations, till 2035
- 12.5.3. Nanoparticle Formulation Services Market for Commercial Operations, till 2035
12.6. Nanoparticle Formulation Services Market: Analysis by Key Geographical Regions
- 12.6.1. Nanoparticle Formulation Services Market in North America, till 2035
- 12.6.2. Nanoparticle Formulation Services Market in Europe, till 2035
- 12.6.3. Nanoparticle Formulation Services Market in Asia-Pacific, till 2035
- 12.6.4. Nanoparticle Formulation Services Market in Middle East and North Africa, till 2035
- 12.6.5. Nanoparticle Formulation Services Market in Latin America, till 2035

13. CASE STUDY: TECHNOLOGY LICENSING DEALS

13.1. Chapter Overview
13.2. Recent Technology Licensing Deals
13.3. Concluding Remarks

14. CONCLUSION

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100437

List of Tables

Table 4.1 Nanoparticle Formulation Technologies: Information on Type of Nanoparticle(s) Formulated
Table 4.2 Nanoparticle Formulation Technologies: Information on Formulation Method(s) Used
Table 4.3 Nanoparticle Formulation Technologies: Information on Type of Molecule(s) Delivered
Table 4.4 Nanoparticle Formulation Technologies: Information on Therapeutic Area(s)
Table 4.5 Nanoparticle Formulation Technologies: Information on Compatible Dosage Form(s)
Table 4.6 Nanoparticle Formulation Technologies: Information on Route(s) of Administration
Table 4.7 Nanoparticle Formulation Technologies: Information on Compatible Drug Release Mechanism
Table 4.8 Nanoparticle Formulation Technologies: Information on Compatibility for Long-Acting Drug Delivery
Table 4.9 Nanoparticle Formulation Technologies: List of Technology Developers
Table 5.1 Nanoparticle Formulation Service Providers: List of Service Providers
Table 5.2 Nanoparticle Formulation Service Providers: Information on Type of Nanoparticle(s) Formulated
Table 5.3 Nanoparticle Formulation Service Providers: Information on Type of Service(s) Offered
Table 5.4 Nanoparticle Formulation Service Providers: Information on Scale of Operation
Table 5.5 Nanoparticle Formulation Service Providers: Information on Application Area(s)
Table 8.1 Nanoparticle Formulation Technology Developers and Service Providers: List of Companies Profiled
Table 8.2 Ascension Sciences: Company Overview
Table 8.3 Ascension Sciences: Technology Portfolio
Table 8.4 Ascension Sciences: Recent Developments and Future Outlook
Table 8.5 DIANT Pharma: Company Overview
Table 8.6 DIANT Pharma: Technology Portfolio
Table 8.7 DIANT Pharma: Recent Developments and Future Outlook
Table 8.8 ExonanoRNA: Company Overview
Table 8.9 ExonanoRNA: Technology Portfolio
Table 8.10 ExonanoRNA: Recent Developments and Future Outlook
Table 8.11 Nanoform: Company Overview
Table 8.12 Nanoform: Technology Portfolio
Table 8.13 Nanoform: Recent Developments and Future Outlook
Table 8.14 NanoVation Therapeutics: Company Overview
Table 8.15 NanoVation Therapeutics: Technology Portfolio
Table 8.16 NanoVation Therapeutics: Recent Developments and Future Outlook
Table 8.17 NanoVelos: Company Overview
Table 8.18 NanoVelos: Technology Portfolio
Table 8.19 NTT Biopharma: Company Overview
Table 8.20 NTT Biopharma: Technology Portfolio
Table 8.21 Organoid-X BioTech: Company Overview
Table 8.22 Organoid-X BioTech: Technology Portfolio
Table 8.23 Vaxinano: Company Overview
Table 8.24 Vaxinano: Technology Portfolio
Table 8.25 Vaxinano: Recent Developments and Future Outlook
Table 9.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership and Type of Partner, since 2018
Table 9.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Continent-wise), since 2018
Table 10.1 Patent Analysis: List of Top CPC Sections
Table 10.2 Patent Analysis: List of Top CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Codes
Table 10.4 Patent Analysis: Categorizations based on Weighted Valuation Scores
Table 10.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 11.1 Organic Nanoparticles: Global Competition
Table 11.2 Inorganic Nanoparticles: Global Competition
Table 11.3 Carbon-based Nanoparticles: Global Competition
Table 13.1 Technology Licensing Deals
Table 16.1 Nanoparticle Formulation Technologies: Distribution by Type of Nanoparticle(s) Formulated
Table 16.2 Nanoparticle Formulation Technologies: Distribution by Type of Organic Nanoparticle(s) Formulated
Table 16.3 Nanoparticle Formulation Technologies: Distribution by Type of Inorganic Nanoparticle(s) Formulated
Table 16.4 Nanoparticle Formulation Technologies: Distribution by Type of Molecule(s) Delivered
Table 16.5 Nanoparticle Formulation Technologies: Distribution by Therapeutic Area(s)
Table 16.6 Nanoparticle Formulation Technologies: Distribution by Compatible Dosage Form(s)
Table 16.7 Nanoparticle Formulation Technologies: Distribution by Route(s) of Administration
Table 16.8 Nanoparticle Formulation Technology Developers: Distribution by Year of Establishment
Table 16.9 Nanoparticle Formulation Technology Developers: Distribution by Company Size
Table 16.10 Nanoparticle Formulation Technology Developers: Distribution by Location of Headquarters
Table 16.11 Nanoparticle Formulation Technology Developers: Distribution by Company Size and Location of Headquarters
Table 16.12 Most Active Players: Distribution by Number of Technologies
Table 16.13 Nanoparticle Formulation Service Providers: Distribution by Year of Establishment
Table 16.14 Nanoparticle Formulation Service Providers: Distribution by Company Size
Table 16.15 Nanoparticle Formulation Service Providers: Distribution by Location of Headquarters
Table 16.16 Nanoparticle Formulation Service Providers: Distribution by Company Size and Location of Headquarters
Table 16.17 Nanoparticle Formulation Service Providers: Distribution by Location of Facilities
Table 16.18 Nanoparticle Formulation Service Providers: Distribution by Type of Service Provider(s)
Table 16.19 Nanoparticle Formulation Service Providers: Distribution by Type of Nanoparticle(s) Formulated
Table 16.20 Nanoparticle Formulation Service Providers: Distribution by Type of Organic Nanoparticle(s) Formulated
Table 16.21 Nanoparticle Formulation Service Providers: Distribution by Type of Inorganic Nanoparticle(s) Formulated
Table 16.22 Nanoparticle Formulation Service Providers: Distribution by Type of Service Provider(s) and Type of Nanoparticle(s) Formulated
Table 16.23 Nanoparticle Formulation Service Providers: Distribution by Type of Service(s) Offered
Table 16.24 Nanoparticle Formulation Service Providers: Distribution by Company Size and Type of Service(s) Offered
Table 16.25 Nanoparticle Formulation Service Providers: Distribution by Scale of Operation
Table 16.26 Nanoparticle Formulation Service Providers: Distribution by Application Area(s)
Table 16.27 Partnerships and Collaborations: Distribution by Year of Partnership
Table 16.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 16.30 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.31 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 16.32 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Table 16.33 Most Active Players: Distribution by Number of Partnerships
Table 16.34 Partnerships and Collaborations: Distribution by Region
Table 16.35 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 16.36 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 16.37 Patent Analysis: Distribution by Type of Patent
Table 16.38 Patent Analysis: Cumulative Distribution by Publication Year, since 2018
Table 16.39 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 16.40 Patent Analysis: Distribution by Geography
Table 16.41 Patent Analysis: Distribution by CPC Symbols
Table 16.42 Leading Industry Players: Distribution by Number of Patents
Table 16.43 Patent Analysis: Cumulative Distribution by Type of Organization
Table 16.44 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Table 16.45 Patent Analysis: Distribution by Patent Age
Table 16.46 Organic Nanoparticles: Number of Clinical Trials
Table 16.47 Organic Nanoparticles: Extent of Innovation (Number of Patents)
Table 16.48 Organic Nanoparticles: Trends in Research Activity (Number of Publications)
Table 16.49 Inorganic Nanoparticles: Number of Clinical Trials
Table 16.50 Inorganic Nanoparticles: Extent of Innovation (Number of Patents)
Table 16.51 Inorganic Nanoparticles: Trends in Research Activity (Number of Publications)
Table 16.52 Carbon-based Nanoparticles: Cumulative Number of Clinical Trials
Table 16.53 Carbon-based Nanoparticles: Extent of Innovation (Number of Patents)
Table 16.54 Carbon-based Nanoparticles: Trends in Research Activity (Number of Publications)
Table 16.55 Global Nanoparticle Formulation Services Market, till 2035 (USD Billion)
Table 16.56 Nanoparticle Formulation Services Market: Distribution by Type of Nanoparticle Formulated, Current Year and 2035
Table 16.57 Nanoparticle Formulation Services Market: Distribution by Type of Organic Nanoparticle Formulated, Current Year and 2035
Table 16.58 Nanoparticle Formulation Services Market for Polymeric Nanoparticles, till 2035 (USD Million)
Table 16.59 Nanoparticle Formulation Services Market for Lipid Nanoparticles, till 2035 (USD Million)
Table 16.60 Nanoparticle Formulation Services Market for Viral Nanoparticles, till 2035 (USD Million)
Table 16.61 Nanoparticle Formulation Services Market for Protein-based Nanoparticles, till 2035 (USD Million)
Table 16.62 Nanoparticle Formulation Services Market for Other Organic Nanoparticles, till 2035 (USD Million)
Table 16.63 Nanoparticle Formulation Services Market for Inorganic Nanoparticles, till 2035 (USD Million)
Table 16.64 Nanoparticle Formulation Services Market for Carbon-based Nanoparticles, till 2035 (USD Million)
Table 16.65 Nanoparticle Formulation Services Market: Distribution by Scale of Operation, Current Year and 2035
Table 16.66 Nanoparticle Formulation Services Market for Preclinical Operations, till 2035 (USD Million)
Table 16.67 Nanoparticle Formulation Services Market for Clinical Operations, till 2035 (USD Million)
Table 16.68 Nanoparticle Formulation Services Market for Commercial Operations, till 2035 (USD Million)
Table 16.69 Nanoparticle Formulation Services Market: Distribution by Key Geographical Regions, Current Year and 2035
Table 16.70 Nanoparticle Formulation Services Market in North America, till 2035 (USD Million)
Table 16.71 Nanoparticle Formulation Services Market in Europe, till 2035 (USD Million)
Table 16.72 Nanoparticle Formulation Services Market in Asia-Pacific, till 2035 (USD Million)
Table 16.73 Nanoparticle Formulation Services Market in Middle East and North Africa, till 2035 (USD Million)
Table 16.74 Nanoparticle Formulation Services Market in Latin America, till 2035 (USD Million)

List of Figures

Figure 2.1 Executive Summary: Technology Landscape
Figure 2.2 Executive Summary: Service Providers Landscape
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Patent Analysis
Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Key Benefits and Limitations of Nanoparticle-based Systems
Figure 3.2 Classification of Nanoparticles
Figure 3.3 Applications of Nanoparticle-based Systems
Figure 4.1 Nanoparticle Formulation Technologies: Distribution by Type of Nanoparticle(s) Formulated
Figure 4.2 Nanoparticle Formulation Technologies: Distribution by Type of Organic Nanoparticle(s) Formulated
Figure 4.3 Nanoparticle Formulation Technologies: Distribution by Type of Inorganic Nanoparticle(s) Formulated
Figure 4.4 Nanoparticle Formulation Technologies: Distribution by Type of Molecule(s) Delivered
Figure 4.5 Nanoparticle Formulation Technologies: Distribution by Therapeutic Area(s)
Figure 4.6 Nanoparticle Formulation Technologies: Distribution by Compatible Dosage Form(s)
Figure 4.7 Nanoparticle Formulation Technologies: Distribution by Route(s) of Administration
Figure 4.8 Nanoparticle Formulation Technology Developers: Distribution by Year of Establishment
Figure 4.9 Nanoparticle Formulation Technology Developers: Distribution by Company Size
Figure 4.10 Nanoparticle Formulation Technology Developers: Distribution by Location of Headquarters
Figure 4.11 Nanoparticle Formulation Technology Developers: Distribution by Company Size and Location of Headquarters
Figure 4.12 Most Active Players: Distribution by Number of Technologies
Figure 5.1 Nanoparticle Formulation Service Providers: Distribution by Year of Establishment
Figure 5.2 Nanoparticle Formulation Service Providers: Distribution by Company Size
Figure 5.3 Nanoparticle Formulation Service Providers: Distribution by Location of Headquarters
Figure 5.4 Nanoparticle Formulation Service Providers: Distribution by Company Size and Location of Headquarters
Figure 5.5 Nanoparticle Formulation Service Providers: Distribution by Location of Facilities
Figure 5.6 Nanoparticle Formulation Service Providers: Distribution by Type of Service Provider(s)
Figure 5.7 Nanoparticle Formulation Service Providers: Distribution by Type of Nanoparticle(s) Formulated
Figure 5.8 Nanoparticle Formulation Service Providers: Distribution by Type of Organic Nanoparticle(s) Formulated
Figure 5.9 Nanoparticle Formulation Service Providers: Distribution by Type of Inorganic Nanoparticle(s) Formulated
Figure 5.10 Nanoparticle Formulation Service Providers: Distribution by Type of Service Provider(s) and Type of Nanoparticle(s) Formulated
Figure 5.11 Nanoparticle Formulation Service Providers: Distribution by Type of Service(s) Offered
Figure 5.12 Nanoparticle Formulation Service Providers: Distribution by Company Size and Type of Service(s) Offered
Figure 5.13 Nanoparticle Formulation Service Providers: Distribution by Scale of Operation
Figure 5.14 Nanoparticle Formulation Service Providers: Distribution by Application Area(s)
Figure 6.1 Technology Competitiveness Analysis: Nanoparticle Formulation Technologies Offered by Small Players based in North America
Figure 6.2 Technology Competitiveness Analysis: Nanoparticle Formulation Technologies Offered by Mid-sized and Large Players based in North America
Figure 6.3 Technology Competitiveness Analysis: Nanoparticle Formulation Technologies Offered by Players based in Europe
Figure 6.4 Technology Competitiveness Analysis: Nanoparticle Formulation Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Rest of the World
Figure 7.1 Company Competitiveness Analysis: Nanoparticle Formulation Service Providers based in North America
Figure 7.2 Company Competitiveness Analysis: Nanoparticle Formulation Service Providers based in Europe
Figure 7.3 Company Competitiveness Analysis: Nanoparticle Formulation Service Providers based in Asia-Pacific, and Middle East and North Africa
Figure 8.1 Ascension Sciences: Service Portfolio
Figure 8.2 DIANT Pharma: Service Portfolio
Figure 8.3 ExonanoRNA: Service Portfolio
Figure 8.4 Nanoform: Service Portfolio
Figure 8.5 NanoVation Therapeutics: Service Portfolio
Figure 8.6 NanoVelos: Service Portfolio
Figure 8.7 NTT Biopharma: Service Portfolio
Figure 8.8 Organoid-X BioTech: Service Portfolio
Figure 8.9 Vaxinano: Service Portfolio
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Distribution by Region
Figure 9.9 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 9.10 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, since 2018
Figure 10.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 10.4 Patent Analysis: Distribution by Geography
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Leading Industry Players: Distribution by Number of Patents
Figure 10.7 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 10.8 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Figure 10.9 Patent Analysis: Distribution by Patent Age
Figure 10.10 Patent Analysis: Patent Valuation
Figure 11.1 Organic Nanoparticles: Number of Clinical Trials
Figure 11.2 Organic Nanoparticles: Extent of Innovation (Number of Patents)
Figure 11.3 Organic Nanoparticles: Trends in Research Activity (Number of Publications)
Figure 11.4 Nanoparticle Evaluation Framework: Organic Nanoparticles
Figure 11.5 Inorganic Nanoparticles: Number of Clinical Trials
Figure 11.6 Inorganic Nanoparticles: Extent of Innovation (Number of Patents)
Figure 11.7 Inorganic Nanoparticles: Trends in Research Activity (Number of Publications)
Figure 11.8 Nanoparticle Evaluation Framework: Inorganic Nanoparticles
Figure 11.9 Carbon-based Nanoparticles: Cumulative Number of Clinical Trials
Figure 11.10 Carbon-based Nanoparticles: Extent of Innovation (Number of Patents)
Figure 11.11 Carbon-based Nanoparticles: Trend in Research Activity (Number of Publications)
Figure 11.12 Nanoparticle Evaluation Framework: Carbon-based Nanoparticles
Figure 11.13 Nanoparticle Evaluation Framework: Spider Web Representation
Figure 12.1 Global Nanoparticle Formulation Services Market, till 2035 (USD Billion)
Figure 12.2 Nanoparticle Formulation Services Market: Distribution by Type of Nanoparticle Formulated, Current Year and 2035
Figure 12.3 Nanoparticle Formulation Services Market: Distribution by Type of Organic Nanoparticle Formulated, Current Year and 2035
Figure 12.4 Nanoparticle Formulation Services Market for Polymeric Nanoparticles, till 2035 (USD Million)
Figure 12.5 Nanoparticle Formulation Services Market for Lipid Nanoparticles, till 2035 (USD Million)
Figure 12.6 Nanoparticle Formulation Services Market for Viral Nanoparticles, till 2035 (USD Million)
Figure 12.7 Nanoparticle Formulation Services Market for Protein-based Nanoparticles, till 2035 (USD Million)
Figure 12.8 Nanoparticle Formulation Services Market for Other Organic Nanoparticles, till 2035 (USD Million)
Figure 12.9 Nanoparticle Formulation Services Market for Inorganic Nanoparticles, till 2035 (USD Million)
Figure 12.10 Nanoparticle Formulation Services Market for Carbon-based Nanoparticles, till 2035 (USD Million)
Figure 12.11 Nanoparticle Formulation Services Market: Distribution by Scale of Operation, Current Year and 2035
Figure 12.12 Nanoparticle Formulation Services Market for Preclinical Operations, till 2035 (USD Million)
Figure 12.13 Nanoparticle Formulation Services Market for Clinical Operations, till 2035 (USD Million)
Figure 12.14 Nanoparticle Formulation Services Market for Commercial Operations, till 2035 (USD Million)
Figure 12.15 Nanoparticle Formulation Services Market: Distribution by Key Geographical Regions, Current Year and 2035
Figure 12.16 Nanoparticle Formulation Services Market in North America, till 2035 (USD Million)
Figure 12.17 Nanoparticle Formulation Services Market in Europe, till 2035 (USD Million)
Figure 12.18 Nanoparticle Formulation Services Market in Asia-Pacific, till 2035 (USD Million)
Figure 12.19 Nanoparticle Formulation Services Market in Middle East and North Africa, till 2035 (USD Million)
Figure 12.20 Nanoparticle Formulation Services Market in Latin America, till 2035 (USD Million)
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 14.1 Concluding Remarks: Overall Technology Landscape
Figure 14.2 Concluding Remarks: Overall Service Providers Landscape
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Patent Analysis
Figure 14.5 Concluding Remarks: Market Forecast and Opportunity Analysis

Nanoparticle Formulation Market by Type of Nanoparticle (Organic, Inorganic Nanoparticles and Carbon-based Nanoparticles), Scale of Operation and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

Description

Table of Contents

List of Tables

NANOPARTICLE FORMULATION MARKET: OVERVIEW

NANOPARTICLE FORMULATION MARKET: GROWTH AND TRENDS

NANOPARTICLE FORMULATION MARKET: KEY INSIGHTS

NANOPARTICLE FORMULATION MARKET: KEY SEGMENTS

Example Players in the Nanoparticle Formulation Market

NANOPARTICLE FORMULATION MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. TECHNOLOGY LANDSCAPE

5. SERVICE PROVIDERS LANDSCAPE

6. TECHNOLOGY COMPETITIVENESS ANALYSIS

7. COMPANY COMPETITIVENESS ANALYSIS

8. COMPANY PROFILES

9. PARTNERSHIPS AND COLLABORATIONS

10. PATENT ANALYSIS

11. NANOPARTCLE EVALUATION FRAMEWORK

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

13. CASE STUDY: TECHNOLOGY LICENSING DEALS

14. CONCLUSION

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures